Key facts
- This page summarizes Christopher Bowden's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2021, 16:06.
Christopher Bowden - 07 Jun 2021 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- AGIO
- Reported as of
- 07 Jun 2021
- Net transaction value
- -$222,077
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2021, 16:06:25 UTC
- Next SEC filing
- 11 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Cook, as Attorney-in-fact for Christopher Bowden
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Bowden filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 09 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$222,077.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGIO
transaction
Common stock
Options Exercise
- Transaction value
- $169,696
- Shares
- +4,268
- Change %
- +28%
- Price
- $39.76
- Shares after
- 19,755
- Date
- 07 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
AGIO
transaction
Common stock
Sale
- Transaction value
- $256,232
- Shares
- -4,268
- Change %
- -22%
- Price
- $60.04
- Shares after
- 15,487
- Date
- 07 Jun 2021
- Ownership
- Direct
- Footnotes
- F2, F3
AGIO
transaction
Common stock
Options Exercise
- Transaction value
- $265,398
- Shares
- +6,675
- Change %
- +43%
- Price
- $39.76
- Shares after
- 22,162
- Date
- 08 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
AGIO
transaction
Common stock
Sale
- Transaction value
- $400,939
- Shares
- -6,675
- Change %
- -30%
- Price
- $60.07
- Shares after
- 15,487
- Date
- 08 Jun 2021
- Ownership
- Direct
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGIO
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,268
- Change %
- -9.8%
- Price
- $0.000000
- Shares after
- 39,064
- Date
- 07 Jun 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 4,268
- Exercise price
- $39.76
- Footnotes
- F1, F5
AGIO
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,675
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 32,389
- Date
- 08 Jun 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 6,675
- Exercise price
- $39.76
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F3
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F4
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Footnote F5
This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.